Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMHOTEP: Pembrolizumab in Perioperative Setting for MSI/dMMR Tumors
NCT04795661Phase 2Active, not recruiting
- Sponsor
- Centre Léon Bérard
- Start
- Oct 2021
- Primary completion
- Oct 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in colorectal cancer (CRC), gastric cancer (GC), esophageal cancer, small bowel adenocarcinoma (SBA), sponsored by Centre Léon Bérard. Started Oct 2021; status: active, not recruiting.
02
Drugs
03
Conditions
colorectal cancer (CRC)gastric cancer (GC)esophageal cancersmall bowel adenocarcinoma (SBA)
Beyond the preview
Go deeper on NCT04795661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04795661.